DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
DaVita Inc. filed its Q3 2025 10‑Q, reporting higher revenue and continued buybacks. Total revenues were $3,420,227 thousand, up from $3,263,590 thousand a year ago. Operating income was $505,767 thousand. Net income attributable to DaVita Inc. was $150,332 thousand, with diluted EPS of $2.04.
For the first nine months, revenues reached $10,023,282 thousand and net cash provided by operating activities was $1,345,774 thousand. The company repurchased 3,274 thousand shares in Q3 for $465,141 thousand and 10,001 thousand shares year‑to‑date for $1,461,387 thousand. As of October 28, 2025, approximately 70.6 million shares were outstanding.
DaVita issued $1,000,000 of 6.75% senior notes due 2033 and refinanced into a Term Loan B‑2 of $1,873,254; long‑term debt stood at $10,183,863 thousand. The weighted average effective interest rate on all debt was 5.70% in Q3. The company acquired Fresenius Medical Care’s Brazil dialysis operations for $94,282 thousand, contributing to total 2025 acquisition consideration of $108,015 thousand.
DaVita Inc. furnished an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information is being furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth. Additional materials include Exhibit 104.0 for the cover page Inline XBRL tags.
David Paul Maughan, Chief Operating Officer of DaVita Inc. (DVA), reported a transaction on 09/22/2025. The filing shows 7,501 shares of common stock were disposed of at a price of $130.16 per share through withholding to satisfy tax obligations. Those withheld shares represent 50% of 17,145 restricted stock units that vested for the reporting person from a grant dated September 22, 2022. After the withholding, the reporting person beneficially owns 122,266 shares. The form was signed by an attorney-in-fact on behalf of the reporting person.
DaVita Inc. reported that its board of directors has increased the authorization under its existing share repurchase program by an additional $2,000,000,000. This new repurchase authority is in addition to the amount remaining under the share repurchase program originally authorized on September 5, 2024, and it has no expiration date.
The company is not obligated to buy back any shares and may conduct repurchases in the open market or through privately negotiated transactions, including under its share repurchase agreement dated April 30, 2024 with Berkshire Hathaway Inc., as well as through accelerated share repurchases, derivatives, tender offers or Rule 10b5-1 plans. The timing and size of any repurchases will depend on market conditions, legal and contractual limits, and other factors, and DaVita can modify, suspend or discontinue the program at any time.
DaVita Inc. director Adam H. Schechter reported a non-derivative acquisition of company stock on 08/15/2025. The filing shows 369 shares were acquired with a reported price of $0, leaving the reporting person with 4,699 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 08/19/2025. No derivative transactions or additional remarks are reported in the filing.
Phyllis R. Yale, a director of DaVita Inc. (DVA), reported acquiring 369 shares of DaVita common stock on 08/15/2025 at a reported price of $0. After the reported transaction she beneficially owned 13,570 shares. The Form 4 was filed as an individual filing for one reporting person and was signed by an attorney-in-fact on 08/19/2025.
DaVita Inc. director Barbara J. Desoer, through an attorney-in-fact, reported acquiring 369 shares of DaVita common stock on 08/15/2025 at no cash price indicated on the form and holds 369 shares directly following the transaction. The filing shows she also has indirect beneficial ownership of 12,659 shares through the Marc J. Desoer and Barbara J. Desoer 1998 Trust dated September 7, 1998. The Form 4 was signed by Stephanie N. Berberich as attorney-in-fact on 08/19/2025.
Insider transaction summary: This Form 4 shows that Jason M. Hollar, a director of DaVita Inc. (DVA), acquired 369 shares of DaVita common stock on 08/15/2025. The reported acquisition is coded as A and lists a price of $0, indicating the shares were received without cash payment (e.g., a grant or similar issuance). After the transaction, Mr. Hollar beneficially owned 5,612 shares. The filing was signed by an attorney-in-fact on 08/19/2025.
DaVita Inc. director Gregory J. Moore acquired 369 shares of DaVita common stock on 08/15/2025 at no reported cash price (Code V). After the transaction he beneficially owned 6,820 shares, held directly. The Form 4 discloses this routine insider purchase; no derivative transactions or additional disclosures are reported in the filing.
Wendy L. Schoppert, a director of DaVita Inc. (DVA), reported acquiring 369 shares of DaVita common stock on 08/15/2025 at a reported price of $0. After the transaction she directly owns 369 shares and indirectly owns 2,525 shares through the Wendy L. Schoppert Revocable Trust. The Form 4 was signed by an attorney-in-fact on 08/19/2025. The filing shows a routine insider acquisition by a director and discloses the split between direct and indirect beneficial ownership.